Fighting antimicrobial resistance in sexually transmitted infections with targeted diagnostics
Described as the hidden pandemic, antimicrobial resistance is viewed by many scientists as one of the greatest challenges facing healthcare today and in the future. This was especially highlighted in a recent study published in The Lancet, which found antimicrobial resistance to be the direct cause of at least 1.27 million deaths globally in 2019.
While researchers are developing therapeutics to combat rapidly developing resistance across bacterial species, they now realise that it is equally important to quickly diagnose resistant infections in order to deliver the right treatment, thereby minimising the risk of generating further resistance.
In this webinar, three experts in their fields discuss how they were able to combine their expertise to deliver a resistance-guided therapy approach for the successful treatment and management of sexually transmitted infections (STIs), particularly in Mycoplasma genitalium.
Head of Research Translation and Mentorship, Genital Microbiota and Mycoplasma Group Lead
Melbourne Sexual Health Clinic
Consultant in Sexual Health and HIV, University of Hospitals Sussex Senior Lecturer, Brighton and Sussex Medical School